Table 2.
Clinical characteristics in subjects according to semi-quantitatively assessed RV function.
| Normal RV function | Mild RVD | Moderate to severe RVD |
Across group p value |
Any RVD | |
|---|---|---|---|---|---|
| N | 444 | 65 | 53 | 118 | |
| Age, years | 79 (62-86) | 82 (74-85) | 74 (66-82) † | 0.01 | 79 (69-84) |
| Women, n (%) | 258 (58) | 32 (49) | 30 (57) | 0.40 | 62 (53) |
| BSA, m2 | 1.94 (1.71-2.15) | 1.94 (1.79-2.18) | 1.86 (1.73-2.19) | 0.73 | 1.90 (1.74-2.20) |
| BMI, Kg/m2 | 28.86 (24.7-34.5) | 28.4 (25.6-34.2) | 26.2 (23.5-36.7) | 0.59 | 28.2 (24.1-34.6) |
| Comorbidities | |||||
| Hypertension, n (%) | 379 (85) | 57 (88) | 43 (81) | 0.60 | 100 (85) |
| Diabetes, n (%) | 161 (36) | 19 (29) | 16 (30) | 0.41 | 35 (30) |
| Ever smoker, n (%) | 233 (52) | 40 (62) | 28 (53) | 0.39 | 68 (58) |
| CAD, n (%) | 243 (55) | 40 (62) | 28 (53) | 0.55 | 68 (58) |
| Atrial fibrillation, n (%) | 180 (41) | 43 (66)* | 32 (60) | <0.0001 | 75 (64) † |
| COPD, n (%) | 132 (30) | 24 (37) | 18 (34) | 0.45 | 42 (36) |
| OSA, n (%) | 107 (24) | 20 (31) | 17 (32) | 0.27 | 37 (31) |
| Pacemaker, n (%) | 112 (25) | 25 (38)* | 13 (25) | 0.07 | 38 (32) ‡ |
| GFR, ml/min/1.73m2 (n=333) | 56 (43-68) | 56 (39-66) | 54 (40-82) | 0.84 | 56 (40-70) |
| Hemoglobin, g/dl (n=333) | 12.1 (10.7-13.5) | 11.4 (10.3-12.8) | 12.3 (10.7-13.9) | 0.23 | 11.9 (10.4-13.2) |
| Medications | |||||
| ACE/ARB, n (%) | 217 (49) | 35 (54) | 28 (53) | 0.68 | 63 (53) |
| Beta blocker, n (%) | 284 (64) | 39 (60) | 31 (58) | 0.64 | 70 (59) |
| Diuretics, n (%) | 276 (62) | 47 (72) | 40 (75) | 0.06 | 87 (74) ‡ |
| Statins, n (%) | 215 (48) | 25 (38) | 21 (40) | 0.19 | 46 (39) |
Abbreviations as in Table 1.
*
Mild RVD vs Normal RV function;
†
p< 0.05 Moderate-severe vs mild RVD;
‡
p<0.05 Any RVD vs normal RV function
Across group p value: Difference across the 3 groups of RV function (normal, mild and moderate to severe RVD), Kruskal Wallis test